Portal de Periódicos da CAPES

Tipping the immunostimulatory and inhibitory DAMP balance to harness immunogenic cell death

2020; Nature Portfolio; Volume: 11; Issue: 1 Linguagem: Inglês

10.1038/s41467-020-19970-9

2041-1723

Kazukuni Hayashi, Fotis Nikolos, Y. C. Lee, Antrix Jain, Efrosini Tsouko, Hongbo Gao, Armine Kasabyan, Hon‐Chiu Eastwood Leung, Arsen Osipov, Sung Yun Jung, Antonina V. Kurtova, Keith Syson Chan,

Immune cells in cancer

Abstract Induction of tumor cell death is the therapeutic goal for most anticancer drugs. Yet, a mode of drug-induced cell death, known as immunogenic cell death (ICD), can propagate antitumoral immunity to augment therapeutic efficacy. Currently, the molecular hallmark of ICD features the release of damage-associated molecular patterns (DAMPs) by dying cancer cells. Here, we show that gemcitabine, a standard chemotherapy for various solid tumors, triggers hallmark immunostimualtory DAMP release (e.g., calreticulin, HSP70, and HMGB1); however, is unable to induce ICD. Mechanistic studies reveal gemcitabine concurrently triggers prostaglandin E 2 release as an inhibitory DAMP to counterpoise the adjuvanticity of immunostimulatory DAMPs. Pharmacological blockade of prostaglandin E 2 biosythesis favors CD103 + dendritic cell activation that primes a Tc1-polarized CD8 + T cell response to bolster tumor rejection. Herein, we postulate that an intricate balance between immunostimulatory and inhibitory DAMPs could determine the outcome of drug-induced ICD and pose COX-2/prostaglandin E 2 blockade as a strategy to harness ICD.